September 25, 2018 10:19 AM EDTUpdated 11:34 AM

Takeda highlights promising frontline results for ALK+ NSCLC drug Alunbrig; TGTX shares plunge on PhIII snafu

John Carroll

Editor & Founder

→ Takeda unveiled positive PFS data for its ALK+ NSCLC drug Alunbrig (brigatinib) today, underscoring a hazard ratio of 0.49 — a 51% drop in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda highlights promising frontline results for ALK+ NSCLC drug Alunbrig; TGTX shares plunge on PhIII snafu

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Small personalized vaccine trial sees progress in late-stage kidney cancer

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Revance and Crown are almost ready to close their deal after earlier bidding war

Trump 2.0 blog: Musk's DOGE team searches CMS payment systems for fraud

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Take­da high­lights promis­ing front­line re­sults for ALK+ NSCLC drug Alun­brig; TGTX shares plunge on PhI­II sna­fu

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Takeda highlights promising frontline results for ALK+ NSCLC drug Alunbrig; TGTX shares plunge on PhIII snafu